101
Participants
Start Date
February 9, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
December 31, 2025
Decitabine and Cedazuridine (ASTX727)
Route of administration: oral in the form of a tablet
Venetoclax
Route of administration: oral in the form of a tablet
Weill Cornell Medical College, New York
The Research Foundation of the State University of New York (SUNY), Syracuse
Roswell Park Comprehensive Cancer Center, Buffalo
University of Rochester, Rochester
UPMC Hillman Cancer Center, Pittsburgh
Penn State Milton S. Hershey Medical Center, Hershey
East Carolina University, Greenville
Universitario Gregorio Marañon, Madrid
Clinica Universidad de Navarra, Pamplona, Pamplona
Baptist MD Anderson Cancer Center, Jacksonville
Hospital Universitario Central de Asturias, Oviedo
Boca Raton Clinical Research, Plantation
Hospital Universitario de Salamanca, Salamanca
The Ohio State University, Columbus
Hospital Universitari i Politecnic La Fe, Valencia
Indiana University Simon Cancer Center, Indianapolis
The University of Chicago Medical Center, Chicago
Health Midwest Ventures Group, Inc., Kansas City
Baylor Scott & White Research Institute, Temple
MD Anderson Cancer Center, Houston
USC Norris Comprehensive Cancer Center, Los Angeles
Stanford University, Palo Alto
Seattle Cancer Care Alliance, Seattle
Yale University, New Haven
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
University of Massachusetts, Memorial Medical Center, Worcester
Hackensack University of Medical Center, Hackensack
Vanderbilt University Medical Center, Nashville
University of Calgary - Health Sciences Centre, Calgary
University of Alberta, Edmonton
The Ottawa Hospital, General Campus, Ottawa
Jewish General Hospital, Montreal
Institut Catala d'Oncologia-Hospital Duran i Reynals, L'Hospitalet de Llobregat
Taiho Oncology, Inc.
INDUSTRY